This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

But a pair of treatments that launched in 2019 are already offsetting Humira's losses. Combined sales of Skyrizi, a psoriasis ...

AbbVie (NYSE: ABBV) could be the poster child for how to effectively navigate a patent cliff. When Abbott Labs spun off ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

The dividend is significant to AbbVie: The company is a Dividend King, with a decades-long history of yearly increases from when it was still part of Abbott Labs. Investors can probably expect mid ...